Datasets:

ESGBERT

/

social_data

like 0

Follow

ESGBERT 26

To expedite scientific discovery, we engage in non-clinical research collaborations to provide academic and non-profit research institutions access to our proprietary animal models, cell lines and other technologies.

Through these collaborations, we also provide access to approved medicines or therapeutic pipeline candidates for use in non-human studies.

ADVANCING GENETICS RESEARCH Developing innovative technology and pursuing a deep understanding of human genetics and biology continues to be a priority and a passion.

Enabled through our collaborations with the Geisinger Health System, the UK Biobank and more than Center (RGC) has built one of the world’s largest databases for genomic analysis of health and disease.

Responsibility Report In March Biobank released the first tranche of new human sequencing data to health researchers around the world, offering an unprecedented ‘Big Data’ resource to enhance understanding of human biology and aid in therapeutic discovery.

The exome sequence data of the first UK Biobank participants were generated at the RGC through a collaboration between UK Biobank, Regeneron, and GlaxoSmithKline and are linked to detailed de-identified health records, imaging and other health-related data.

This data is accessible to the global research community via the UK Biobank open access resource, now one of the largest open access resources of exome sequence data linked to robust health records in the world.

Genetics is playing an increasingly important role in research, and the actionable information in this resource means there are infinite discoveries to be made that could potentially benefit human health.

At Regeneron, we know that we can’t do it all alone, and we believe this unprecedented new resource will help the broader scientific community enhance their research efforts and lead to more breakthroughs that could improve patients lives.

Responsibility Report Regeneron has always approached pricing with fairness, affordability and access at the forefront.

Insurance companies restricted patient access to Praluent by attaching complex, multi-step “utilization management” criteria around its use.

Still, access and affordability remained a challenge for patients who were often unable to afford the prescribed medication due to high co-pay costs or co-insurance imposed by health plans.

This includes health insurers and pharmacy benefit managers who play a key role in ensuring affordable access to needed medicines.

IMPROVING LIVES SNAPSHOT / Patient Advocacy Groups Patient advocacy groups represent their respective patient communities’ needs, issues and challenges and also seek to raise awareness, empower patients through education and advocate for patients to receive the best care.

They are critical stakeholders in our work, collaborating with us to address important health issues and improve patient care.

Increasing Disease Awareness We believe patients should be knowledgeable about their disease so they can advocate and make informed decisions around their care.

Under the guidance of patient advocacy groups, we bring patients together with our researchers, clinical development colleagues and health economic outcomes research groups to learn what it means to live with a disease, how patients manage their day-to-day lives and what they and their caregivers want in new therapies.

Supporting Patient Access We believe that patients should have access to appropriate, evidence-based medicines to get them to the best health.

Patients are singularly able to tell their story about access challenges and how these obstacles can impact their daily lives and health.

All too often, these symptoms are more than skin deep too, having an impact on the mental and emotional well-being of people with AD, causing feelings of anxiety, depression and loneliness.

Proposals were reviewed against a pre-defined set of criteria by a panel that included global leaders from the AD community.

We offer product support to both healthcare providers and patients, including contacting patients’ health plans to determine the requirements for coverage and reimbursement and educating healthcare providers and patients on the steps needed to start the patient on the medicine.

In addition to helping patients access their prescribed medicines, some of our patient support programs provide ongoing education to patients about their medicine and how to use it as prescribed by their healthcare provider.

Compassionate Use: Access to Medicines Before a new treatment is widely available to the public, it undergoes rigorous clinical testing to ensure it meets the safety and efficacy criteria required for regulatory approval.

Our Compassionate Use Policy gives certain patients who have serious or life-threatening conditions access to a potentially beneficial medicine.

One way we demonstrate our commitment to doing the right thing and to applying our technologies effectively is through our efforts to respond to public health challenges like infectious disease outbreaks.

It was a perfect opportunity to pair our desire to improve global health with our proprietary VelociSuite® of drug discovery and development technologies.

Instead, we tested the investigational medicine in a healthy-volunteer Phase demonstrating its safety in humans.

Building on our Ebola and Middle East Respiratory Syndrome (MERS) coronavirus experience and using the same VelociSuite® technologies, we are collaborating to rapidly develop a novel antibody cocktail that could be used as a preventative or treatment to combat this latest significant global health risk.

These shared values and behaviors guide our efforts to recruit and retain the best and brightest from today’s talent marketplace.

Our culture of integrity informs how we approach all areas of our business, from R&D and product quality and safety, through to sales and marketing and supply chain management.

Transparency We believe greater transparency helps the public understand how we collaborate with the medical community to deliver safe and effective therapies and helps patients make more informed healthcare decisions.

Our opendoor policy encourages people to raise any concerns or questions with their supervisor or manager, by contacting the Head of Human Resources or Chief Compliance Officer or by making anonymous reports through our EthicsPoint hotline (877-RGN-ETHX) or website.

CSOdemonstrate outstanding business value and thought leadership Information Security and Data Privacy Cybersecurity is critical to companies operating in our increasingly digital world, where sensitive data, personal information and intellectual property are vulnerable to theft or damage.

For us to retain trust and continue to grow, we need to ensure we are maintaining robust systems to protect against threats, both technological and human.

Our patients, colleagues, partners and other stakeholders trust Regeneron to protect the privacy of their personal data and we treat this responsibility with the utmost seriousness.

Privacy is a legal landscape that is rapidly expanding, and we are continually analyzing new and changing laws to ensure our compliance.

We updated our online Privacy Policy and put controls in place to align with new regulations, such as the EU General Data Protection Regulation (GDPR), which has been in place since the California Consumer Privacy Act, which came into effect on January 1, 2020.

PRIVACY IS A PART OF THAT, AND EACH OF US PLAYS AN IMPORTANT ROLE IN PRIVACY AND COMPLIANCE.

As a general matter, this support is made to office holders and candidates who hold views that are consistent with, or will further, the legislative, regulatory and public policy goals of our company, patients and community.

We adhere to the highest ethical standards in our activities, respecting and following all applicable federal, state and local laws.

We believe it is our responsibility to engage on public health matters, and we are focused on supporting Regeneron’s mission to bring important new medicines to people living with serious diseases.

Our policies provide clear requirements for promotional materials and communications to employees, contingent workforce and vendors who communicate with the healthcare community.

• Our Protocol Review Committee confirms that ethics and patient safety considerations are fully integrated into all of our trial protocols.

• Our Data Privacy Office has developed processes to ensure the privacy protections of participants in our clinical trials.

When we outsource studies to contract research organizations (CROs), our Good Clinical Practices (GCP) audit program reviews clinical trials and associated internal systems, vendors and clinical investigators to confirm they meet our quality and safety standards and are compliant, and to identify meaningful corrective and preventive actions.

We are also subject to external audits by health authority inspectors that verify that we are complying with ethical standards and applicable laws and regulations.

As part of this effort, in of processes and controls to increase awareness and incorporate diversity considerations into the design and placement of our clinical studies.

We support data transparency that advances science and medicine, protects participant privacy and is in the best interest of individuals who use our products and providers who prescribe them.

Regardless of study outcome, Regeneron seeks to publish its Phase studies and its hypothesis testing/confirming Phase 1 and 2 studies; post-approval clinical studies conducted to meet a regulatory requirement; post-approval observational studies with predefined hypotheses that involve a Regeneron product; and any other clinical trial or study that provides important information on the safety and/or efficacy/ effectiveness of the agent under investigation.

Qualified researchers may request access to individual patient or aggregate-level data from a Regeneron-sponsored study by submitting a research proposal to https://vivli.org/. Animal Welfare Regeneron is committed to and abides by all ethical requirements related to animal welfare in research, teaching and testing.

QUALITY AND SAFETY Our ability to meet patients’ unmet needs depends on providing safe, high-quality products that people can trust.

The safety of our patients is our top priority and critical to delivering on our mission. products.

We are committed to our responsibility for timely reporting of safety information to the FDA and other regulatory authorities, in compliance with regulations and global expectations.

It gives us the peace of mind that patients are receiving genuine products.

We regularly monitor suppliers’ financial and operational stability by assessing criteria such as financial stress, quality management, safety compliance, conflict mineral traceability, information security and compliance with applicable laws and regulations, including those related to anti-bribery and anticorruption.

We assess suppliers annually against various criteria including risk, regulatory compliance, safety, quality and criticality to the business.

The Code sets out expectations for ethical practices on issues such as business integrity and fair competition, animal welfare, clinical trials, privacy, transparency and reporting.

We require that suppliers uphold the human rights of workers in accordance with applicable laws and treat them with dignity and respect.

We continue to target six certified diverse supplier groups: Small Business, Veteran Owned, Service Disabled Veteran Owned, Women-Owned Small Business, Small Disadvantaged and HUBZone.

Still, we operate in a competitive industry where top talent, particularly people with STEM skills, is in high demand.

As we continue to grow, we are making significant investments to attract, engage and develop the workforce we require to bring new medicines to patients in need.

TALENT ATTRACTION AND RETENTION Regeneron’s success is measured by our ability to deliver on our promise to repeatedly bring important new medicines to people with serious diseases.

Designed to meet the needs of our growing workforce, many of whom are millennials and/or not desk-based, the app will engage them with easily digestible content, photos and videos, infographics and sharing, commenting and chat capabilities.

Welcoming our first recruits in of four on-the-job training phases with Regeneron and three off-the-job phases with Solas, Ireland’s post-secondary education and training organization.

As a global company serving a diverse patient community, we recognize that every experience, perspective and idea that our employees contribute enriches our ability to create and innovate.

As we grow, we believe it’s important that our talent pool represents people from all walks of life.

Providing Jobs for People with Intellectual and Developmental Disabilities We recognize a diverse workforce is critical to generating novel ideas and fostering the innovation required to bring new medicines to people in need.

We are also taking a critical look at our talent management processes, including recruitment and performance management, to assess to what degree they may be impacted by unconscious bias.

And, we expect to roll out an augmented writing platform to gender-neutralize our job descriptions.

Diverse by gender, race or national origin 5. 56% of our independent directors are diverse by gender, race or national origin Building Inclusion Through Employee Interest Groups Since 2017, our grassroots, employee-led advocacy and interest groups have offered a valuable platform to build inclusion.

Resilience is Essential, Toastmasters and our new group Regeneron Players Guild, an employee club focused on creating a community of people who enjoy playing tabletop role-playing games.

Given that more women graduate from colleges and universities than men, and increasingly with science, technology, engineering and math degrees, attracting and retaining their talent is critical as we grow.

Our global Women in Science and Engineering at Regeneron (WISER) EIG provides an inclusive platform for networking and mentorship while supporting women through professional development, well-being and community outreach activities.

WISER hosted a number of activities in on International Women’s Day from Sally Paull, our Senior Vice President of Human Resources, who spoke about the value of developing strong collegial relationships and building an inclusive work environment to attain collective success.

The group also hosts careerdevelopment and mentoring workshops, health awareness sessions and Day for Doing Good activities.

TalentHub provides a one-stop learning center that helps employees develop and grow in their careers through instant access to Regeneron’s library of more than trainings, instructional videos and educational materials.

This tool specifies relevant skills, abilities and timelines for career development and promotion across different departments.

We assess our compensation and rewards programs annually to ensure that we are competitive in the marketplace, while at the same time focusing our efforts on fairness and internal equity.

COMPENSATION, BENEFITS AND RECOGNITION Regeneron’s compensation, benefits and recognition philosophy focuses on supporting our employees by providing programs that are consistent with our unique culture and support the diversity of our employees at all stages of family life.

Inclusive Benefits Regeneron supports our employees and their families by providing a competitive benefits package that includes health benefits and retirement savings option, as well as support for work-life balance, education and wellbeing.

We also increased bereavement leave to which can be used over six months from the date of loss, to give employees more time to grieve and support family members.

SNAPSHOT / Education Support Supporting employee continuing education is an important part of our benefits compensation.

Education reimbursement of up to $a year for tuition and books.

Additional programs range from health biometrics screenings to desk yoga and massage therapy.

In engagement tool to encourage participation incentives, challenges and health trackers.

The health and safety of all of our employees is critical to our success.

We meet or exceed all environmental, health, safety (EHS) and security regulations and have a range of programs, plans and procedures to ensure the safety of all people who come to work at Regeneron.

We adhere to the standards set by local occupational health and safety regulatory bodies, such as the Occupational Safety and Health Administration (OSHA) and the Ireland Health & Safety Authority.

This report data covered laboratory safety, near misses, ergonomics and other health and safety metrics.

It helped facilitate regular safety-related discussions between R&D leaders and laboratory personnel, increasing employee engagement and accountability.

Our SLIM (Simple, Logical Improvements Matter) program challenges every employee to continuously look for opportunities to improve safety, quality and efficiencies.

In participated in the SLIM program, marking the highest level of participation to date and resulting in the implementation of 3,834 new continuous improvements to improve the health and safety of our workplace.

Regeneron’s mission to use the power of science to address serious medical conditions is strengthened by our long-term commitments to protect the health of the planet, inspire future generations of scientists and engage our employees as stewards in their communities.

The link between planetary health and human health is increasingly evident.

This includes the practices codified in our updated Environmental, Health and Safety Policy, which we published in 2019.

Our employee-led green teams help embed and promote sustainability practices, and we use incentives and host corporate-wide events such as Earth Week to encourage our workforce to actively contribute to our efforts in the workplace and in our communities.

Our owned, renewable energy resources support regulatory compliance and reduce the carbon footprint of our operations As greenhouse gas (GHG) emissions continue to increase and global temperatures rise, we understand the far-reaching impacts of climate change, including water scarcity, ecosystem disturbance and short- and long-term risks to human health, access to medicine and supply chain reliability.

Limerick employees continue to raise awareness in the workplace and the larger community about the need to preserve bee and other pollinator species that are threatened with extinction.

At our Rensselaer campus, we have restored a “forever wild” nature preserve and developed community gardens.